新冠疫苗与合并症对接受卡西瑞单抗-伊德维单抗治疗患者的影响:SARS-CoV-2 B.1.617.2(Delta) surge期间的真实世界研究
本研究在SARS-CoV-2 B.1.617.2(Delta)变异株流行期间,对接受卡西瑞单抗-伊德维单抗输注的3586例COVID-19阳性患者进行真实世界分析,比较全程接种与未全程接种者的合并症及28天全因和COVID相关急诊就诊或住院率。结果显示COVID相关住院与合并症数量直接相关(OR 1.745),全程接种降低住院可能性(OR 0.472)并缩短住院时间(2天 vs 4.5天)。
要点
- 全程接种者28天COVID相关住院时间较未全程接种者缩短(2天 vs 4.5天,p<0.001)。
- 合并症数量增加与COVID相关住院风险升高相关(OR 1.745,95%CI 1.469-2.074)。
- 全程接种降低COVID相关住院可能性(OR 0.472,95%CI 0.239-0.933)。
核心结论
- COVID疫苗接种状态和合并症是卡西瑞单抗-伊德维单抗治疗后结局的显著预测因素。
- 尽管合并症更多,输注时全程接种的患者住院时间更短且28天COVID急诊就诊或住院减少。
- 未来试验还应基于患者疫苗接种状态比较结局。
研究设计与样本
- 真实世界研究,分析Delta surge期间接受卡西瑞单抗-伊德维单抗输注的COVID-19阳性患者共3586例。
- 比较全程接种与未全程接种个体的基础合并症及28天全因和COVID相关急诊就诊或住院率。
主要发现
- COVID相关住院与合并症数量直接相关(OR 1.745,95%CI 1.469-2.074)。
- 全程接种且合并症≥3种的患者28天COVID相关急诊就诊或住院率较低(p=0.044)。
- 全程接种且合并症≥4种的患者28天全因急诊就诊或住院率较低(p=0.029)。
- 高血压(OR 2.418,95%CI 1.341-4.360)、免疫抑制状态(OR 5.250,95%CI 1.912-14.417)、年龄≥65岁(OR 4.045,95%CI 2.224-7.358)增加COVID相关住院概率;全程接种降低住院可能性(OR 0.472,95%CI 0.239-0.933)。
- 全程接种患者COVID相关住院时间较未全程接种者缩短(2天 vs 4.5天,p<0.001)。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Several randomized trials and real-world studies depicted the role of monoclonal antibody infusion in reducing hospitalization, and halting progression from asymptomatic to symptomatic COVID pneumonia, viral titer, and death. No data exists to show outcomes of patients who received casirivimab-imdevimab infusion based on their vaccination status and underlying comorbidities. This study aims to provide outcomes of casirivimab-imdevimab treatment during the SARS-CoV-2 B1.617.2 (Delta) surge among fully vaccinated and not fully vaccinated individuals. METHODS: COVID-19-positive patients who received casirivimab-imdevimab infusion during the Delta surge were analyzed to compare their underlying comorbidities and the rate of 28-days all-cause and COVID-related ED visits or hospitalization, among fully vaccinated and not fully vaccinated individuals. RESULTS: A total of 3,586 patients received casirivimab-imdevimab infusion. COVID-related hospitalizations were directly related to the number of comorbidities (OR:1.745, 95 % CI:1.469-2.074). Vaccinated patients with ≥3 comorbidities had lower rates of 28-day COVID-related ED visits or hospitalization (p = 0.044) and those with ≥4 comorbidities had lower rates of 28-day All-cause ED visits or hospitalization (p = 0.029). Hypertension (OR:2.418, 95 %CI:1.341-4.360), immunocompromised state (OR:5.250, 95 %CI: 1.912-14.417), age ≥ 65 (OR:4.045, 95 %CI:2.224-7.358) increased the probability of hospitalization due to COVID and being fully vaccinated lowered the likelihood of hospitalization (OR: 0.472, 95 %CI: 0.239-0.933). Vaccinated patients had a lower length of COVID-related hospitalization (2 days vs 4.5 days, p < 0.001). CONCLUSION: COVID vaccination status and comorbidities are significant predictors of outcomes after casirivimab-imdevimab treatment. Despite having higher comorbidities, patients who were fully vaccinated at the time of casirivimab-imdevimab infusion had a lower length of hospitalization and reduced 28-day COVID ED visits or hospitalizations. Future trials should also compare outcomes based on the patient's vaccination status.
引用
- Agrawal P, Damania D, Cseh A, et al. Impact of COVID vaccine and comorbidities in patients receiving casirivimab-imdevimab monoclonal antibody during SARS-CoV-2 B.1.617.2 (Delta) surge: A real-world study. Vaccine. 2023. PMID: 37451874. doi:10.1016/j.vaccine.2023.07.011
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。